Understanding Clinical Trial Phases: From Phase 1 to Phase 4

What each clinical trial phase means, how long they take, success rates by phase, and what the phases tell you about a treatment's progress toward FDA approval.

Medical Information Only. This guide is educational. Consult your healthcare provider about clinical trial participation.
Not Applicable86577Phase 231395Phase 130052Phase 315530Phase 49318Early Phase 12766
How US clinical trials currently break down by reported phase, live from the ClinicalTrials.gov registry. Many studies report no applicable phase (observational or expanded-access).

Pre-Clinical Research

Before human testing begins, potential treatments undergo laboratory testing and animal studies. This pre-clinical phase identifies promising compounds, establishes basic safety parameters, and determines appropriate starting doses for human testing. Only a fraction of compounds that show promise in pre-clinical testing advance to human trials. The pre-clinical phase can take 3-6 years.

Phase 1: Safety and Dosage

Phase 1 trials are the first human tests of a new treatment. They enroll a small number of participants (typically 20-100), often healthy volunteers, to evaluate safety, determine safe dosage ranges, and identify side effects. In oncology, Phase 1 trials often enroll patients with advanced cancer who have exhausted other options, since cancer drugs are too toxic to test on healthy volunteers. About 70% of drugs pass Phase 1.

Phase 2: Efficacy and Side Effects

Phase 2 trials test whether the treatment works for the target condition. They enroll 100-300 patients with the condition being studied and measure both effectiveness and side effects. This is the highest-risk phase, about 67% of drugs fail in Phase 2, often because they do not demonstrate sufficient efficacy over existing treatments or placebo. Phase 2 trials are typically randomized and may be blinded.

Phase 3: Confirmation in Large Populations

Phase 3 trials are large-scale studies enrolling 1,000-3,000+ participants across multiple sites. They compare the new treatment to the current standard of care or placebo using randomized, double-blind methodology. Phase 3 data is what the FDA reviews for approval decisions. Successful Phase 3 trials lead to a New Drug Application (NDA) or Biologics License Application (BLA). About 58% of drugs that enter Phase 3 eventually receive approval.

Phase 4: Post-Market Surveillance

Phase 4 trials occur after FDA approval and monitor the treatment in the general population over longer time periods. They can identify rare side effects that did not appear in the smaller Phase 3 population, study long-term outcomes, and evaluate the treatment in special populations (elderly, children, pregnant women) that may have been excluded from earlier phases.

Phase Success Rates by Therapeutic Area

Success rates vary dramatically by disease area. Oncology clinical trials historically have the lowest success rates, approximately 5-7% of cancer drugs entering Phase 1 ultimately receive FDA approval, compared to roughly 20% for cardiovascular drugs and 15% for infectious disease treatments. Rare disease treatments have seen improving success rates as the FDA has created more flexible regulatory pathways for conditions affecting small patient populations.

The reasons for these differences are complex. Cancer is biologically heterogeneous, what works for one tumor type may fail in another. Many oncology trials test drugs in late-stage patients who have already failed multiple treatments, creating a challenging patient population. Cardiovascular drugs benefit from well-established biomarkers and large patient pools for enrollment. The growing use of precision medicine (matching drugs to specific genetic mutations) is improving success rates in oncology but adding complexity to trial design.

Only about 1 in 7 drugs that enter Phase 1 ever reaches patients, most fail in Phase 2, where efficacy is tested for the first time.
Historical FDA approval rates

Adaptive Trial Designs

Traditional clinical trials follow a fixed protocol from start to finish. Adaptive trial designs allow modifications based on interim results, adjusting doses, dropping ineffective treatment arms, enriching for responsive patient populations, or increasing enrollment in promising arms. These designs can reduce the time and cost of development while maintaining statistical rigor. The FDA has actively encouraged adaptive approaches, particularly since 2019 when it published detailed guidance on adaptive designs.

Expedited Pathways

The FDA offers several expedited programs for treatments addressing serious conditions with unmet medical needs. Fast Track designation provides more frequent FDA meetings and rolling review of the application. Breakthrough Therapy designation offers intensive FDA guidance from Phase 1 onward. Accelerated Approval allows approval based on surrogate endpoints (laboratory measures that predict clinical benefit rather than directly measuring it). Priority Review shortens the FDA review timeline from the standard 10 months to 6 months. These programs can significantly reduce the development timeline but do not lower the evidence bar for approval.

The Emergency Use Authorization (EUA) pathway, used extensively during the COVID-19 pandemic, allows temporary authorization of unapproved products during declared emergencies. EUA requires less evidence than full approval but includes post-authorization monitoring requirements. Products authorized under EUA must eventually complete the standard approval process to remain on the market after the emergency declaration ends.

Understanding Phase Terminology on PlainTrial

On PlainTrial, each trial's phase is displayed as reported by the sponsor on ClinicalTrials.gov. You will see Phase 1, Phase 2, Phase 3, Phase 4, and "Early Phase 1" (formerly called "Phase 0" - small studies testing very low doses to understand how a drug behaves in the body before committing to full Phase 1 testing). Some trials list "Phase 1/Phase 2" or "Phase 2/Phase 3" - these are combined-phase designs that blend objectives from two phases into a single study to accelerate the timeline.

Trials marked "Not Applicable" for phase are typically non-drug studies such as behavioral interventions, medical device trials, surgical technique comparisons, or diagnostic studies. These studies follow different regulatory pathways and may not fit neatly into the traditional four-phase framework designed primarily for drug development.

Understanding the phase of a trial helps you gauge how much is already known about a treatment's safety and efficacy. Earlier-phase trials carry more uncertainty but may offer access to cutting-edge therapies. Later-phase trials have more established safety profiles but may require comparison to existing treatments including placebo. Your healthcare provider can help you evaluate which phase is most appropriate given your condition, treatment history, and personal preferences regarding risk tolerance.

Key Takeaways

Phase 1 establishes safety in small groups. Phase 2 tests whether the treatment works. Phase 3 confirms effectiveness at scale. Phase 4 monitors long-term outcomes after approval. Success rates improve at later phases, but most drugs still fail before reaching patients.

Frequently Asked Questions

What are the phases of clinical trials?

Clinical trials progress through four phases: Phase 1 tests safety and dosage in a small group (20-100 people). Phase 2 tests efficacy and side effects in a larger group (100-300). Phase 3 confirms effectiveness in large populations (1,000-3,000+) and compares to existing treatments. Phase 4 occurs after FDA approval to monitor long-term effects in the general population.

What percentage of clinical trials succeed?

Historically, about 14% of drugs entering Phase 1 eventually receive FDA approval. Success rates improve at later phases: roughly 67% of Phase 1 trials advance to Phase 2, about 31% of Phase 2 advance to Phase 3, and approximately 58% of Phase 3 trials succeed. These rates vary significantly by therapeutic area, oncology has lower success rates than cardiovascular drugs.

How long does each phase take?

Phase 1 typically takes 1-2 years. Phase 2 takes 2-3 years. Phase 3 takes 3-4 years. Phase 4 is ongoing post-approval. The total development timeline from initial discovery to FDA approval averages 10-15 years. Some trials proceed faster under FDA expedited programs (Fast Track, Breakthrough Therapy, Accelerated Approval).